Vimarsana
Biggest News Aggregation in the World

Science Box News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Science Box. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Science Box Today - Breaking & Trending Today

Keep fit to avoid heart rhythm disorder and s - Vimarsana News

Keep fit to avoid heart rhythm disorder and s

A study in more than 15,000 people has found that physical fitness is linked with a lower likelihood of developing atrial fibrillation and stroke. The research is presented at ESC Congress 2023. Atrial fibrillation is the most common heart rhythm disorder, affecting more than 40 million people worldwide.2 It is estimated that one in three Europeans will develop atrial fibrillation in their lifetime. Patients with the condition have a five-fold higher risk of stroke than their peers. This study examined whether fitness was related to the likelihood of developing atrial fibrillation.

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023 - Vimarsana News

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

THE WOODLANDS, Texas, Aug. 21, 2023 -- Lexicon Pharmaceuticals, Inc. today announced that analyses of clinical study results relating to INPEFA™ , its recently approved drug for heart...

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing ... - Vimarsana News

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing ...

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress - Vimarsana News

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 -- Amarin Corporation plc today announced the acceptance of funded research for presentation at the European Society of Cardiology Congress,...